Pediatric and Geriatric Pharmacology — MCQs
Pseudotumor Cerebri in Infants is seen with?
Which of the following factors influences the duration of action of a drug?
Which of the following is the most appropriate treatment for an overactive bladder in a patient with dementia?
All the following drugs are teratogenic except?
Which of the following antidepressants can be safely used in elderly depression?
Which of the following statements about the differences between neonates and adults is true?
A drug is more likely to cause toxicity in elderly patients due to all of the following reasons except which of the following?
A child presented with a history of ingestion of an unknown plant and developed mydriasis, tachycardia, dry mouth, warm skin, and delirium. Which of the following groups of drugs is likely to be responsible for the symptoms of this child?
What is the treatment of choice for a 5-year-old child with bedwetting?
Which drug is commonly used to mitigate the side effects of haloperidol?
Pediatric and Geriatric Pharmacology Indian Medical PG Practice Questions and MCQs
Question 1: Pseudotumor Cerebri in Infants is seen with?
- A. Aminoglycosides
- B. Tetracyclines (Correct Answer)
- C. Macrolides
- D. NSAIDs
Explanation: ***Tetracyclines***- **Tetracyclines**, particularly in infants, are a known cause of **pseudotumor cerebri**, also known as **idiopathic intracranial hypertension (IIH)**. - This condition involves increased **intracranial pressure (ICP)**, leading to symptoms like **headache**, **visual disturbances**, and **papilledema**. *Aminoglycosides*- **Aminoglycosides** are primarily associated with **ototoxicity** (hearing loss) and **nephrotoxicity** (kidney damage) [1]. - They are not typically linked to the development of **pseudotumor cerebri**. *NSAIDS*- **NSAIDs** (Nonsteroidal Anti-inflammatory Drugs) are more commonly associated with **gastrointestinal ulcers** and **renal impairment**. - While they can have neurological side effects in some cases, **pseudotumor cerebri** is not a characteristic or common adverse effect. *Macrolides*- **Macrolides** like erythromycin or azithromycin are generally well-tolerated and are primarily associated with **gastrointestinal upset** and **QT prolongation**. - There is no significant evidence linking **macrolide use** to the development of **pseudotumor cerebri**.
Question 2: Which of the following factors influences the duration of action of a drug?
- A. Bioavailability
- B. Clearance
- C. Rate of elimination
- D. All of the options (Correct Answer)
Explanation: ***All of the options*** - **Clearance** and **rate of elimination** are the primary determinants of how long a drug stays in the body at therapeutic levels, thus directly influencing its duration of action. - **Bioavailability** affects the intensity and onset but can influence the perceived duration if subtherapeutic concentrations are achieved. - The interplay of these pharmacokinetic parameters ultimately determines the drug's therapeutic window and frequency of dosing. *Clearance* - **Clearance** is the rate at which the active drug is removed from the body, primarily by the kidneys and liver. - A higher clearance generally leads to a shorter elimination half-life and a **shorter duration of action**, as the drug is removed more quickly from the systemic circulation. *Rate of elimination* - The **rate of elimination** directly dictates how quickly the concentration of a drug in the body decreases over time. - A faster elimination rate (shorter half-life) means the drug's effects will wear off sooner, resulting in a **shorter duration of action**. - This is quantified by the elimination rate constant (Kel) and half-life (t½). *Bioavailability* - **Bioavailability** refers to the fraction of an administered dose of unchanged drug that reaches the systemic circulation. - While bioavailability primarily affects the **peak concentration (Cmax)** and **intensity** of drug effect, it can indirectly influence duration. - If bioavailability is very low, therapeutic concentrations may not be sustained long enough, effectively shortening the **clinically relevant duration of action**. - However, two drugs with identical elimination rates but different bioavailabilities will have the same elimination half-life and similar duration at therapeutic doses.
Question 3: Which of the following is the most appropriate treatment for an overactive bladder in a patient with dementia?
- A. Tolterodine (Correct Answer)
- B. Mirabegron
- C. Behavioral therapy/bladder training
- D. Oxybutynin
- E. Trospium
Explanation: ***Tolterodine*** - **Tolterodine** is a **muscarinic antagonist** that blocks acetylcholine receptors in the bladder, reducing detrusor muscle contractions and overactive bladder symptoms. - Unlike some other anticholinergics like oxybutynin, it has a **lower propensity to cross the blood-brain barrier** and thus a reduced risk of exacerbating cognitive impairment in patients with dementia. *Mirabegron* - **Mirabegron** is a **beta-3 adrenergic agonist** that relaxes the detrusor muscle, increasing bladder capacity. - While it has a different mechanism of action and is less likely to cause anticholinergic cognitive side effects than older anticholinergics, it can still cause **hypertension** and **tachycardia**, which may be problematic in elderly patients with comorbidities. *Behavioral therapy/bladder training* - **Behavioral therapy** and **bladder training** are important first-line treatments for overactive bladder. - However, for patients with **dementia**, cognitive impairment often makes adherence to and understanding of these complex therapies challenging or impossible without significant caregiver support. *Oxybutynin* - **Oxybutynin** is an **anticholinergic drug** that is effective for overactive bladder. - However, it has a **high affinity for muscarinic receptors** in the brain and readily crosses the blood-brain barrier, significantly increasing the risk of **cognitive impairment, confusion, and delirium** in elderly patients, especially those with pre-existing dementia. *Trospium* - **Trospium** is a **quaternary amine anticholinergic** that is hydrophilic and has minimal blood-brain barrier penetration. - While theoretically safer than oxybutynin in terms of CNS effects, it has **lower bladder selectivity** compared to tolterodine and may cause more peripheral anticholinergic side effects (dry mouth, constipation).
Question 4: All the following drugs are teratogenic except?
- A. Alcohol
- B. Phenytoin
- C. Warfarin
- D. Metoclopramide (Correct Answer)
Explanation: ***Metoclopramide*** - **Metoclopramide** is an antiemetic and prokinetic agent generally considered **safe during pregnancy**. - It does **not** have established teratogenic effects and is often used to treat **nausea and vomiting** in pregnant women. *Alcohol* - **Alcohol** is a well-known teratogen, leading to **fetal alcohol syndrome** characterized by facial dysmorphia, growth restriction, and CNS abnormalities. - Even moderate consumption can have detrimental effects on fetal development, particularly brain development. *Phenytoin* - **Phenytoin** is an antiepileptic drug associated with **fetal hydantoin syndrome**, which includes craniofacial anomalies, mental deficits, and distal phalangeal hypoplasia. - It interferes with **folate metabolism** and can increase the risk of neural tube defects. *Warfarin* - **Warfarin** is an anticoagulant that can cause **fetal warfarin syndrome** when used during the first trimester, leading to chondrodysplasia punctata, nasal hypoplasia, and skeletal abnormalities. - Its mechanism involves interfering with **vitamin K-dependent coagulation factors**, affecting fetal bone and cartilage development.
Question 5: Which of the following antidepressants can be safely used in elderly depression?
- A. phenelzine
- B. mirtazapine (Correct Answer)
- C. fluoxetine
- D. trazodone
Explanation: ***Mirtazapine*** - Mirtazapine is often a good choice in elderly patients because it has a relatively **favorable side effect profile** in this population, causing less anticholinergic effects and orthostatic hypotension compared to many other antidepressants. - Its **sedating properties** can be beneficial for elderly patients who also suffer from insomnia, and its **appetite-stimulating effects** can help those with poor nutritional intake. *Phenelzine* - Phenelzine is a **monoamine oxidase inhibitor (MAOI)**, which carries a significant risk of **hypertensive crisis** due to interactions with tyramine-rich foods and many medications, making it generally unsafe for elderly use. - It also has a high incidence of other side effects, including **orthostatic hypotension** and **sedation**, which are particularly dangerous in older adults. *Fluoxetine* - Fluoxetine, an **SSRI**, has a very **long half-life** and can accumulate in elderly patients, increasing the risk of side effects like hyponatremia, gastrointestinal upset, and agitation. - While effective, its **activating properties** can exacerbate anxiety or insomnia in some elderly individuals, and there's a risk of **drug-drug interactions** due to its potent CYP2D6 inhibition. *Trazodone* - Trazodone is primarily used off-label at low doses for **insomnia** due to its prominent sedative effects, but it can cause significant **orthostatic hypotension** and cardiac arrhythmias in the elderly at antidepressant doses. - There is also a risk of **priapism** in men, and its strong sedative properties can lead to increased falls risk and daytime sleepiness, which are undesirable in the elderly.
Question 6: Which of the following statements about the differences between neonates and adults is true?
- A. They can tolerate large doses of certain drugs on body weight basis.
- B. Their excretory ability of the kidney is less well developed. (Correct Answer)
- C. Their gastric emptying is prolonged.
- D. Their hepatic metabolizing enzyme activity is slower.
Explanation: ***Their excretory ability of the kidney is less well developed.*** - Neonates have **immature renal function** with lower glomerular filtration rate (GFR) and tubular secretion/reabsorption capabilities compared to adults. - This reduced excretory capacity affects the **elimination of renally cleared drugs**, often requiring dose adjustments. - This is a **universally accepted true statement** about neonatal physiology. *Their gastric emptying is prolonged.* - While gastric emptying in neonates is indeed slower and more variable than in adults, the statement as written is **somewhat ambiguous** because "prolonged" could be interpreted different ways. - However, **this statement is also factually TRUE** - neonatal gastric emptying IS prolonged compared to adults. - **Note:** This creates ambiguity as both this and the correct answer are true statements. *They can tolerate large doses of certain drugs on body weight basis.* - This is **FALSE** - Neonates generally have **reduced drug tolerance** compared to adults due to immature organ systems. - They are **more susceptible to adverse drug effects** and typically require lower mg/kg doses for most medications. - This is the only clearly **incorrect** statement among the options. *Their hepatic metabolizing enzyme activity is slower.* - This is **TRUE** - The activity of many hepatic drug-metabolizing enzymes (e.g., **cytochrome P450 enzymes**, glucuronidation) is **reduced at birth**. - This slower metabolism can lead to **prolonged half-lives** and increased drug accumulation. - **Note:** This statement is also factually accurate, creating potential ambiguity. **Clinical Note:** This question has inherent ambiguity as three of the four statements are medically accurate. In exam context, the renal excretion option is selected as it represents the most fundamental and clinically significant difference affecting drug dosing in neonates.
Question 7: A drug is more likely to cause toxicity in elderly patients due to all of the following reasons except which of the following?
- A. decreased renal excretion of drugs
- B. decreased hepatic metabolism
- C. decreased volume of distribution (Correct Answer)
- D. increased receptor sensitivity
Explanation: ***decreased volume of distribution*** - A **decreased volume of distribution** would generally lead to a higher peak plasma concentration for a given dose, potentially increasing drug effect and thus toxicity, particularly for **hydrophilic drugs**. - However, for drugs that primarily distribute into **fat** or have a large volume of distribution, age-related changes in body composition (e.g., increased body fat, decreased total body water) can actually lead to an **increased volume of distribution** for some lipophilic drugs. *decreased renal excretion of drugs* - **Aging** is associated with a decline in **glomerular filtration rate (GFR)** and **renal tubular function**, leading to reduced drug clearance. - This results in a longer **half-life** and accumulation of renally excreted drugs, increasing the risk of **toxicity**. *decreased hepatic metabolism* - Liver size, blood flow, and the activity of some **cytochrome P450 enzymes** may decrease with age. - This leads to reduced **first-pass metabolism** and slower systemic clearance of many hepatically metabolized drugs, increasing their **bioavailability** and plasma concentrations. *increased receptor sensitivity* - Elderly patients often exhibit altered **pharmacodynamic responses**, including **increased sensitivity** to certain drugs. - This means a lower concentration of the drug at the receptor site can produce a greater therapeutic or toxic effect, making them more susceptible to **adverse drug reactions**.
Question 8: A child presented with a history of ingestion of an unknown plant and developed mydriasis, tachycardia, dry mouth, warm skin, and delirium. Which of the following groups of drugs is likely to be responsible for the symptoms of this child?
- A. Anticholinergic (Correct Answer)
- B. Sympathomimetic
- C. Opioid
- D. Benzodiazepine
Explanation: ***Anticholinergic*** - The constellation of mydriasis, tachycardia, dry mouth, warm skin, and delirium is classic for **anticholinergic toxicity**, often described as "hot as a hare, blind as a bat, dry as a bone, red as a beet, and mad as a hatter." - This toxidrome is caused by the blockade of **muscarinic acetylcholine receptors**, leading to widespread inhibition of parasympathetic nervous system functions. - Common plant sources include **Datura** (jimsonweed) and **Atropa belladonna** (deadly nightshade). *Sympathomimetic* - While **mydriasis** and **tachycardia** can be present, sympathomimetic toxicity typically causes **diaphoresis (sweating)** and **hypertension**, not dry skin and mouth. - Patients often present with agitation, paranoia, and potentially seizures, but the key differentiating factor is the presence of profuse sweating. *Opioid* - Opioid overdose is characterized by the classic triad of **miosis (pinpoint pupils)**, **respiratory depression**, and **CNS depression (coma)**, none of which are present in this case. - Other common symptoms include bradycardia, hypotension, and hypothermia, which are contrary to the child's presentation. *Benzodiazepine* - Benzodiazepine overdose typically causes **CNS depression** including drowsiness, ataxia, and slurred speech, but usually spares vital signs unless combined with other depressants. - **Mydriasis**, **tachycardia**, and **dry mouth** are not characteristic symptoms of benzodiazepine toxicity; pupils are typically normal or slightly dilated due to hypoxia in severe cases.
Question 9: What is the treatment of choice for a 5-year-old child with bedwetting?
- A. No treatment
- B. Motivational therapy (Correct Answer)
- C. Imipramine
- D. Desmopressin
Explanation: ***Motivational therapy*** - This is the **first-line active treatment** for **primary nocturnal enuresis** in children, involving encouragement, positive reinforcement (star charts), rewards, and education about bladder control. - It focuses on **behavioral strategies** and can be highly effective with parental involvement. - When intervention is pursued at age 5, motivational therapy is preferred over pharmacological options due to safety and effectiveness. *No treatment* - At age 5, **watchful waiting with reassurance** is often appropriate since nocturnal enuresis is common at this age (affects 15-20% of 5-year-olds) and has a **spontaneous resolution rate of 15% per year**. - However, when the question asks for "treatment of choice," it implies active intervention rather than observation alone. - Active behavioral therapy is preferred when bedwetting causes distress or affects the child's self-esteem. *Imipramine* - **Imipramine** is a **tricyclic antidepressant** with anticholinergic effects that can reduce bladder contractions, but it has significant side effects including **cardiac arrhythmias** and is **not first-line treatment**. - It is typically reserved for children ≥7 years after behavioral interventions fail, due to its potential adverse effects and high relapse rate after discontinuation. *Desmopressin* - **Desmopressin** is an **antidiuretic hormone analog** that reduces urine production overnight. - While effective, it is typically reserved for children ≥6 years who are unresponsive to behavioral therapy or for **short-term situational use** (e.g., sleepovers, camps). - Side effects include potential **hyponatremia** and high relapse rate after discontinuation.
Question 10: Which drug is commonly used to mitigate the side effects of haloperidol?
- A. Clozapine
- B. Imipramine
- C. Benztropine (Correct Answer)
- D. Haloperidol
Explanation: ***Correct Option C: Benztropine*** - **Benztropine** is an **anticholinergic medication** commonly used to treat **extrapyramidal symptoms (EPS)** induced by antipsychotics like haloperidol - EPS, such as **dystonia**, **akathisia**, and **parkinsonism**, occur due to dopaminergic blockade in the nigrostriatal pathway - Benztropine works by blocking muscarinic receptors, helping to restore the dopamine-acetylcholine balance in the basal ganglia *Incorrect Option A: Clozapine* - **Clozapine** is an **atypical antipsychotic** known for its effectiveness in **treatment-resistant schizophrenia** and a lower risk of EPS compared to typical antipsychotics - However, it is not used to mitigate existing side effects of other antipsychotics due to its unique side effect profile, including agranulocytosis and myocarditis - Clozapine is a therapeutic alternative, not a treatment for EPS *Incorrect Option B: Imipramine* - **Imipramine** is a **tricyclic antidepressant (TCA)** primarily used to treat **depression** and **anxiety disorders** - It does not have properties that would mitigate the extrapyramidal side effects induced by antipsychotics - TCAs have anticholinergic properties but are not used for EPS management *Incorrect Option D: Haloperidol* - **Haloperidol** is a **typical antipsychotic** itself, and it is the drug whose side effects (e.g., EPS) are being mitigated - Administering more haloperidol would exacerbate, not mitigate, its side effects - This is the causative agent, not the treatment
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free